To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.

Bill 119 HR 1843, also known as the "Increasing Transparency in Generic Drug Applications Act," aims to amend the Federal Food, Drug, and Cosmetic Act in order to enhance transparency in the process of approving generic drugs. The bill seeks to address concerns about the lack of transparency in the generic drug application process, which can lead to delays in bringing affordable medications to market.

Specifically, the bill includes provisions that require the Food and Drug Administration (FDA) to publish information about the status of generic drug applications on its website. This information would include the date of submission, the current status of the application, and any reasons for delays in approval. By making this information publicly available, the bill aims to increase accountability and transparency in the generic drug approval process.

Additionally, the bill includes provisions that require the FDA to provide more detailed explanations for any delays in approving generic drug applications. This would help to ensure that the FDA is held accountable for any delays and provide greater transparency for both drug manufacturers and consumers. Overall, Bill 119 HR 1843 seeks to improve the transparency of the generic drug approval process in order to facilitate the timely approval of affordable medications. By increasing transparency and accountability, the bill aims to ensure that generic drugs are brought to market in a timely manner, ultimately benefiting consumers by increasing access to affordable medications.